The incidence of cerebral infarction is increased in patients with NFPA irrespective of GHRT. Patients without GHRT had an increased risk of T2DM, whereas patients with GHRT, had a normal incidence of T2DM, despite having higher BMI. Incidence of malignant tumours was not increased. Thus, long-term GHRT seems to be safe regarding risk of comorbidities.